Articles tagged with Molecular Imaging
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has selected 7 new Fellows for their exceptional achievements in the field. The SNMMI Fellowship is a prestigious recognition of outstanding service to the society and excellence in scientific discovery, educational efforts, or clinical practice.
A novel molecular imaging agent targeting glypican-3 has demonstrated high sensitivity and specificity in detecting hepatocellular carcinoma (HCC), including tumors smaller than one centimeter. The agent provides high-contrast images of GPC3-positive liver tumors, offering a promising new tool for early diagnosis and staging of HCC.
Researchers used PET imaging to map brain inflammation in PAOS patients, finding distinct patterns that correlate with tau pathology and Parkinson-plus syndrome. The study provides new insights into neuroinflammation's role in disease progression and may lead to earlier diagnosis and targeted treatments.
A new PET radiotracer can detect a wide range of mold species linked to life-threatening infections in cancer and transplant patients. The imaging agent, 18F-FDS, has the potential to dramatically enhance diagnosis and monitoring of invasive mold infections.
A new peptide-based PET tracer outperforms FDG PET in measuring PD-L1 expression in head and neck cancers. The tracer's uptake strongly correlates with PD-L1 levels, suggesting its potential for personalized treatment strategies.
A newly developed cardiac PET imaging technique offers a simpler way to detect significant coronary artery disease by eliminating the need for complex scanning protocols. The technique has been shown to accurately estimate myocardial flow reserve during both exercise and pharmacologic stress, making advanced heart imaging more accessible.
Shannon Youngblood, a seasoned nuclear medicine professional, has been elected as President-Elect of the SNMMI Technologist Section. She aims to elevate visibility and recognition for nuclear medicine professionals through advocacy, promote diversity and inclusion in the workforce, and advance education and professional development. Wi...
Julie C. Price has been recognized for her groundbreaking work on PET imaging techniques and multimodal imaging for translational neuroscience. She aims to advance early detection of Alzheimer's disease-related tau protein deposition.
A novel integrated molecular imaging approach using dual PET/MR and PET/CMR techniques enables precise localization of heart damage and accurate identification of disease subtypes. This method also provides direct evidence supporting surgery as a cardio-protective intervention in patients with primary aldosteronism.
Cybil Nielsen has been elected as the new president of the SNMMI Technologist Section, with a focus on expanding educational programs, mentorship opportunities, and networking events. She aims to promote the recognition and advancement of nuclear medicine technologists within the healthcare landscape.
Wynn Volkert, a renowned expert in nuclear medicine, has been awarded the 2025 SNMMI Georg Charles de Hevesy Nuclear Pioneer Award. He made significant contributions to radiopharmaceutical development, including FDA-approved agents for brain and bone imaging.
Advanced software is used to measure radiation dose distribution throughout the body, ensuring patient safety and tailoring treatments. Post-therapy imaging helps identify complications and guide clinical decisions, ultimately optimizing treatment outcomes and protecting patients.
Two new PET imaging agents have been developed to identify the histamine H3 receptor, which regulates learning, memory, and sleep. These novel tracers show high brain uptake, excellent specificity, and improved in vivo stability.
A new PET imaging technique has successfully visualized three radiotracers in a single scan, enabling a more comprehensive molecular profile of disease. This innovation offers the potential to deliver greater precision in both diagnosis and therapeutic assessment, particularly for complex diseases like cancer.
A new brain imaging platform combining upright PET scanning, AR eye tracking, and motion tracking enables researchers to study brain function in a more natural and dynamic way. This approach offers a more realistic view of brain activity, holding promise for earlier detection of cognitive disorders.
Researchers found that low blood flow at rest may predict heart failure or death, while low stress flow may indicate heart attack risk. A new PET scan method also showed promise for Alzheimer's detection with high accuracy and minimal discomfort.
A novel immuno-PET/CT imaging technique has identified a potent biomarker for nasopharyngeal cancer (NPC), CD70, which is highly expressed in NPCs. The technique showed 100% detection rate of primary tumors and 93% detection rate of local lymph node metastasis in patients with early-stage disease.
New radioimmunotherapy approaches show promise against advanced breast cancer and prostate cancer. Additionally, new imaging tools enhance cancer detection and diagnosis, while a proposed standard improves lesion interpretation. Cost-effectiveness studies also support novel therapies for rare digestive cancers.
A newly developed molecular imaging technique can identify multiple subtypes of triple-negative breast cancer, improving diagnostic capacity. The approach targets extra domain A of fibronectin, a stable protein in the tumor stromal environment abundantly expressed in breast cancer.
Researchers studied obesity's impact on breast cancer, linked imaging patterns to lung disease survival, and tracked hidden inflammation in COVID-19 patients using advanced PET imaging techniques.
New studies explore peptide receptor radionuclide therapy, targeted radiation for prostate cancer, and neuroendocrine tumor treatment. Targeted radiation boosts survival in colorectal liver cancer and bone metastases, while a new PET imaging tracer shows promise for detection.
Scientists have developed a novel pretargeting system to boost cancer imaging using DARPin G3, which achieves specific tumor targeting with reduced kidney and liver uptake. GRPR is emerging as a powerful tool for both imaging and treatment in various cancers, offering personalized cancer care across multiple tumor types.
Scientists have developed a new PET imaging compound to visualize key enzymes in mental health, enabling multiple same-day scans. Additionally, researchers have discovered that PET scans can detect not only HER2-positive but also HER2-low breast cancer lesions.
Researchers have developed new imaging tools to visualize protein changes in Alzheimer's, heart and lung issues in long COVID patients, and a common marker in nasopharyngeal cancer. A first-in-human trial tests a next-generation radiopharmaceutical for advanced prostate cancer.
Researchers developed a new method for imaging enzyme activity in whole organs with high-resolution 3D mapping. This allowed them to visualize differences in aminopeptidase N activity and the effects of inhibitors in mouse kidneys. The study opens up an unbiased evaluation method for drug development.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
Researchers have discovered important differences in how a targeted therapy behaves in the body over time, allowing for more tailored treatment strategies. A new PET/CT scanner also shows promise for accurate imaging with dramatically reduced exposure, especially for sensitive patients like children or those needing repeated scans.
The breakthrough allows researchers to non-invasively assess BBB permeability using a wide range of radiotracers, enabling early detection of altered permeability and potential markers for neurodegenerative diseases. The scanner can also measure the effects of aging and liver inflammation on BBB health.
Researchers have developed a new method that uses expansion microscopy to overcome the spatial resolution problem in mass spectrometry imaging. This allows scientists to detect hundreds of biomolecules at the single cell level in their native locations, enabling better understanding of their functions and interactions.
Researchers have developed novel imaging agents targeting shared proteins in triple-negative breast cancer tumors, successfully highlighting various tumor types using PET/CT scans. Additionally, a new brain imaging technique shows promise in identifying complex brain diseases like progressive supranuclear palsy and corticobasal degener...
A novel radiolabeled antibody targeting the cancer antigen IL13Rα2 has been developed with high specificity for diagnosing and treating solid tumors. The antibody was effective in delineating malignancies at a low injected mass dose, making it a potential candidate for radioimmunotherapy applications.
A new microscopy technique, SIMIP, combines structured illumination with mid-infrared photothermal detection to achieve high-speed chemical imaging with superior resolution. The method outperforms conventional methods in terms of spatial resolution and chemical contrast.
Researchers discovered rare cases of prostate cancer spreading to the testicles using advanced PSMA PET/CT scans, changing how doctors monitor recurring prostate cancer. A new ultra-low-dose PET scanning method reduced radiation exposure without compromising diagnostic image quality in cancer and metabolic imaging.
A study using cryo-electron microscopy revealed that autoantibodies in myasthenia gravis disrupt acetylcholine receptor function by blocking or activating the immune system's complement pathway. This knowledge helps explain treatment variability and offers a foundation for personalized therapies targeting specific antibody interactions.
Two new studies published in The Journal of Nuclear Medicine explore innovative approaches to treating melanoma with radiation therapy and enhancing brain PET imaging. A third study validates an AI network for brain tumor imaging, demonstrating promising results.
A team of chemists from Virginia Tech found a way to visualize the intricate structure and chemical reactions of battery interfaces using an X-ray beam line. This breakthrough enables researchers to gain better control over these critical surfaces, potentially leading to cheaper, higher performance batteries.
Researchers have developed a new way to map how individual connections between neurons change across the entire brain during learning. The method, DELTA, provides a brain-wide map of how individual synaptic proteins change over time, allowing scientists to understand how synaptic connections change and pinpoint areas of the brain impor...
Researchers have confirmed a neurobiochemical link between dopamine and cognitive flexibility through PET imaging, showing increased dopamine production with cognitively demanding tasks. This finding may lead to the development of more precise treatment strategies for neurological and psychiatric disorders.
A novel PET imaging approach has effectively quantified the COX-2 enzyme in human brains, opening doors for its use in clinical settings for various brain disorders. This breakthrough could lead to earlier disease detection and monitor disease progression with anti-inflammatory treatments.
New research published in The Journal of Nuclear Medicine explores ways to improve the diagnosis and treatment of metastatic breast cancer using Ga-NeoB PET/CT. Additionally, studies examine the potential of paraaminohippurate to reduce kidney toxicity during radiopharmaceutical therapy.
The device enables precise control over terahertz wave polarization, revolutionizing applications such as data transmission, imaging, and sensing. This innovation promises to transform fields like wireless communication and biomedical imaging.
Researchers explore new techniques to improve prostate cancer diagnosis and treatment, including dual-target PET/CT for enhanced lymph node staging and novel PSMA-targeted radioligands for more precise tumor targeting.
Researchers use advanced imaging to study molecular movement through NPCs, finding that molecules move through narrow conduits and avoid congestion despite slow movement. This discovery could lead to new insights into conditions like neurodegenerative diseases and cancers.
Conjugated small molecular nanoparticles (CSMNs) have shown promise in near-infrared phototheranostics (NIR PTs) for imaging, therapy, and synergistic treatment. Strategies to improve performances and extend absorption wavelengths are crucial for their clinical translations.
The Chinese Medical Association has released updated guidelines for pediatric mycoplasma pneumoniae infection, emphasizing a multi-faceted diagnostic approach and evidence-based treatment strategies. The guidelines highlight the importance of accurate diagnosis and responsible antibiotic use to combat rising resistance.
Researchers used novel fluorogen imaging techniques to visualize biomolecular condensates, revealing distinct environmental and structural features. The study provides insights into the dynamic behavior of these condensates, which play a crucial role in various diseases.
Researchers have developed a powerful imaging technology to study cellular metabolism, enabling the visualization of biomolecules' synthesis and turnover in live cells and organisms. Heavy-water probing allows for the tracking of metabolic dynamics, providing insights into aging and age-related diseases.
A new PET radiotracer effectively visualizes Nectin-4, a biomarker found in triple-negative breast cancer (TNBC), with the potential to improve clinical outcomes. Researchers developed a series of Nectin-4-targeted radiotracers and evaluated their efficacy in detecting TNBC.
A new technique called cycleHCR uses DNA barcodes to track hundreds of RNA and protein molecules in single cells within thick biological samples. This allows researchers to decipher how genes function in different parts of an organism, how they enable development, and how they might be altered in diseases.
Researchers used X-ray light to analyze the structure of 2-thiouracil, a substance with medically relevant properties. The study found that UV radiation causes the molecule to bend, resulting in the protrusion of the sulfur atom and making it reactive.
Researchers at POSTECH developed a super-photostable organic dye, PF555, to track proteins in cells over extended periods. This breakthrough enables observation of endocytosis and protein interactions, revealing EGFR's active navigation in its environment.
A new universal photocage modification strategy based on thioketal enables real-time live cell subcellular imaging. The thioketal-based probe SiR-EDT exhibits improved dark stability and can be specifically activated by UV-visible light.
A new PET tracer has been developed to visualize intact nerve connections in the spinal cord, which may indicate a better chance of recovery. This breakthrough has the potential to help diagnose injuries more precisely, monitor recovery, and evaluate the effectiveness of new therapies.
A new hybrid microscope allows scientists to image the full 3D orientation and position of an ensemble of molecules, such as labeled proteins inside cells. This can reveal the real biology hidden from just a position change of a molecule alone.
The FORESIGHT consortium aims to improve drug development through advanced nuclear and optical imaging techniques, AI expertise, and infrastructure. This will enable more efficient tracking of drug behavior in the body and better development of imaging biomarkers.
A panel of experts identified key biomarkers for PND through a comprehensive literature review of 194 clinical studies. The study highlights the potential for these biomarkers to predict and diagnose PND, improving postoperative cognitive health in elderly patients.
The University of Texas MD Anderson Cancer Center received nearly $23 million in CPRIT funding to advance cancer research, translational science, and clinical trials. The funding will support the recruitment of a first-time tenure-track faculty member and enhance the understanding of cancer biology.
A team led by Prof. Woo Young Jang developed a novel fluorescent probe to visualize cancer stem cells in complex samples, offering a new direction for cancer diagnostic imaging. This technology has significant implications for diagnosing and monitoring sarcomas.
Next-generation tau radiotracers demonstrate higher binding to Alzheimer's disease brain tissue and greater selectivity than existing imaging agents. This could lead to improved diagnosis and staging of the disease, as well as better outcomes in clinical trials.
A global team of scientists has made a groundbreaking discovery of a new skeletal tissue called lipocartilage, composed of fat-filled cells that provide super-stable internal support. This unique tissue has immense potential for treating facial defects, birth injuries, and cartilage-related conditions.